Phase 1 AQUAx Clinical Trial

We are currently conducting the AQUAx clinical study to evaluate the safety of our investigational gene therapy AAV-hAQP1 and its potential to relieve symptoms of xerostomia. This multi-site Phase 1 clinical trial is enrolling participants who have been diagnosed with grade 2 or 3 radiation-induced xerostomia (RIX) and who have remained cancer free for at least five years (or two years if HPV+) after receiving radiation treatment for head and neck cancer.


Find more information about this clinical trial at